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Abstract: 
Background and Purpose: In randomised stroke trials, central adjudication of a trial’s primary 
outcome is regularly implemented. However, recent evidence questions the importance of central 
adjudication in randomised trials. The aim of this review was to compare outcomes assessed by 
central adjudicators with outcomes assessed by site investigators.   
Methods: We included randomised stroke trials where the primary outcome had undergone 
assessment by site investigators and central adjudicators. We searched MEDLINE, EMBASE, the 
Cochrane Central Register of Controlled Trials, Web of Science, PsycINFO and Google Scholar for 
eligible studies. We extracted information about the adjudication process as well as the treatment 
effect for the primary outcome, assessed both by central adjudicators and by site investigators. We 
calculated the ratio of these treatment effects (RTE) so that an RTE > 1 indicated that central 
adjudication resulted in a more beneficial treatment effect than assessment by site investigator. A 
random-effects meta-analysis model was fitted to estimate a pooled effect. 
Results: Fifteen trials including 69,560 participants were included. The primary outcomes included 
were stroke (8/15, 53%), a composite event including stroke (6/15, 40%) and functional outcome after 
stroke measured on the modified Rankin Scale (1/15, 7%). The majority of site investigators were 
blind to treatment allocation (9/15, 60%). On average, there was no difference in treatment effect 
estimates based on data from central adjudicators and site investigators (pooled RTE=1.02, 95% C.I: 
[0.95, 1.09]).  
Conclusions: We found no evidence that central adjudication of the primary outcome in stroke trials 
had any impact on trial conclusions. This suggests that potential advantages of central adjudication 
may not outweigh cost and time disadvantages in stroke studies if the primary purpose of adjudication 
is to ensure validity of trial findings. 
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Introduction: 
Central adjudication in randomised trials refers to the evaluation of outcome data by independent 
experts who are typically part of an event or outcome adjudication committee[1, 2]. Events and 
outcomes can alternatively be assessed by local site investigators, and central adjudication is 
frequently seen as a marker of clinical trial quality as it is believed to ensure validity of trial results[3], 
such that regulatory authorities have specified the importance of adjudication in guidelines[4, 5]. The 
adjudication process is thought to improve the precision of treatment estimates by reducing random or 
systematic errors[6, 7]. Furthermore, in open-label studies, adjudication has the potential to limit 
detection bias as adjudicators are unaware of treatment allocation[8]. 
Adjudication is regularly implemented in cardiovascular trials[9], but there is inconsistent evidence as 
to the effect of adjudication on trial endpoints in this clinical setting[1, 2, 7, 10-15]. Central adjudication is 
potentially a costly and timely process[6, 10], and, given that many trials are publicly funded, it is 
important to assess adjudication to ensure that trials have efficient design, conduct and analysis[16], as 
well as sufficient but not excessive regulation and management[17]. A Cochrane review[18] found no 
evidence that adjudication of subjective events in randomised trials had any impact on treatment 
estimates, but suggested that adjudication might have most effect on outcomes when site 
investigators are not blinded to treatment allocation. 
In stroke medicine, secondary analysis of trial data suggests that adjudication makes no meaningful 
difference to the endpoints of stroke[10] or functional outcome[19]. Adjudication of serious adverse 
events and stroke type in an acute stroke trial showed that adjudication did not alter trial 
conclusions[20, 21]; in contrast, a simulation study suggested that adjudicating the modified Rankin 
scale (mRS) in acute stroke trials could lead to sample size reductions of up to 20%[22].  
The aim of this review was to investigate the effects on the primary results of stroke trials when using 
outcomes assessed by central adjudicators compared with outcomes assessed by site investigators. 
In addition, we aimed to describe which type(s) of stroke trials have adjudicated outcomes, what 
outcomes are adjudicated and how adjudication has been conducted.  
Methods: 
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This systematic review and meta-analysis was performed following the PRISMA (Preferred Reporting 
Items for Systematic Review and Meta-Analyses) statement. The review protocol can be found at 
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=56731. Supporting, but not 
individual patient, data are available from the corresponding author on reasonable request upon 
receipt of a data sharing and use agreement.  
Eligibility Criteria: 
Studies were eligible for inclusion if they (1) described a randomised trial; (2) described a stroke trial, 
where the participants were either being treated for stroke, or being given an intervention to prevent 
stroke; and (3) the primary outcome had undergone assessment by both site investigators and central 
adjudicators, with the trial providing data to calculate a treatment effect for the primary outcome 
assessed by both central adjudicators and site investigators separately. ‘Site investigator’ is a global 
term describing the persons involved in the trial who assess outcome(s) at each research site where 
study participants are recruited and treated. ‘Adjudicator’ refers to one or more assessors, 
independent from site investigators, who use information collected in the trial to assess the same 
outcome.  
Outcomes collected: 
The primary outcome of each trial was included in this review. If the stroke trial had more than two 
trial arms then all comparisons were included, but for factorial trials only one comparison was 
selected. We accounted for the correlation between comparisons that used the same control group by 
calculating an adjusted weight for the trial based on this additional correlation. Continuous, binary and 
categorical (ordinal and nominal) outcomes were eligible, as were subjective and objective outcomes. 
Search Strategy: 
We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), 
Web of Science, PsycINFO and Google Scholar for relevant articles (searches from database 
inception until 6th November 2018, see Supplemental material). Only the first 300 articles from Google 
Scholar were screened, which is the amount recommended by Haddaway et al.[23] to find sufficient 
grey literature. There were no restrictions on the year of publication. Articles not written in English 
were recorded but excluded.  
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Selection of Studies: 
Duplicate references were identified, recorded and then discarded. One review author (PJG) 
screened all titles and abstracts in the initial screening. A second review author (AAM) screened the 
title and abstract of a random sample of 100 records to check this process. If it was unclear from the 
title and abstract whether the record was eligible then the full text was sought. If the article clearly 
described a secondary analysis of a trial, then the full-text records were only obtained if the record 
mentioned adjudication as well as satisfying eligibility criteria 1 and 2.  
Full text reports were acquired for all records where potential eligibility was unclear. Thus, studies 
could have multiple records (e.g. main results and protocol paper). In the full text screening, studies 
had to satisfy all eligibility criteria to be included in the review. Studies were assessed for inclusion by 
one review author (PJG), with another review author (AAM) checking the process by assessing a total 
of 50 random full texts. 
Data Extraction: 
Data from eligible studies were extracted independently by two authors (PJG, EP) using a piloted data 
extraction form. Disagreements were resolved by discussion between both review authors. If 
agreement could not be reached then one further review author (AAM) assessed the study, with the 
majority decision taken. We recorded whether the central adjudicators and site investigators were 
blind to treatment allocation, the number and profession of adjudicators, the information that was 
provided to the adjudicators, the process for adjudication including decision making and how 
disagreements between adjudicators were dealt with.  
It was anticipated that outcomes assessed by site investigators would not be reported in trial 
publications. Therefore, if essential information was not reported, we emailed the contact author and 
requested unreported data[24]. 
Assessment of risk of bias: 
For each included study, we used the Cochrane risk of bias tool[25] to assess study quality. 
Additionally, we assessed risk of bias associated with the process of selecting cases for adjudication, 
and we have termed this “adjudication risk of bias”. If central adjudicators only assess cases identified 
by site investigators then some bias may remain, particularly if site investigators are not blind to 
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treatment allocation and potentially have a biased view of the relative effectiveness of the treatments 
being compared. We created four categories for adjudication risk of bias: (1) Only cases identified by 
site investigators not blind to treatment allocation were selected for adjudication (High risk of bias); (2) 
Only cases identified by site investigators blind to treatment allocation were selected for adjudication 
(Medium risk of bias); (3) Either all participants, or all suspected cases (e.g. using computer algorithm 
to identify possible cases) were selected for adjudication (Low risk of bias); (4) It is not clear how 
cases were selected for adjudication (Unclear risk of bias).  
Statistical Analysis: 
Continuous variables were summarised with mean and standard deviation, or median and 
interquartile range. Categorical variables were described with frequency counts and percentages. 
Mann-Whitney U tests, Chi-square tests and Fisher exact tests were used to assess comparability 
between included and potentially eligible but excluded studies. 
To compare outcome assessment by central adjudicators and site investigators we calculated the 
ratio of treatment effects (RTE) for each trial. The RTE was determined as the treatment effect 
estimate using outcomes assessed by site investigators to the treatment effect estimate using 
outcomes assessed by central adjudicators. An RTE > 1 indicated that central adjudication resulted in 
a more beneficial treatment effect. Data were pooled, if appropriate, in a meta-analysis using a 
DerSimonian and Laird random-effects model. 
To establish whether central adjudication led to a change in the number of events reported, 
irrespective of the RTE, we compared the number of events reported by site investigators to the 
number reported after central adjudication for each trial. An odds ratio (OR) > 1 indicates that central 
adjudication led to more events reported. For trials that used the ordinal mRS, we dichotomised so 
that a score of 3 and above indicated an event. As before, data were pooled in a meta-analysis using 
a random-effects model. 
The I2-statistic was used to quantify the level of heterogeneity between studies. Subgroup analyses 
and meta-regression were used to investigate heterogeneity. We tested the interaction between the 
RTE and the following: (1) Adjudication risk of bias (high risk/medium risk/low risk/unclear risk); (2) 
Blinding status of site investigators (blind to allocation/not blind to allocation); (3) Type of intervention 
(drug/surgery/other); (4) Sample size of trial (continuous); (5) Number of sites (continuous). A 
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sensitivity analysis for the meta-analysis of RTEs was carried out using a fixed-effect model. All 
analyses were performed in Stata version 15.1 or later.  
Results: 
Search Results: 
Database searches identified 6,339 records and yielded 15 trials of 69,560 participants that were 
eligible for inclusion[26-40] (Figure 1, see Supplementary material, Supplementary Table I). An 
additional 74 trials were potentially eligible, but did not report outcomes assessed by site 
investigators.  
Characteristics of the potentially eligible trials: 
Table 1 shows the characteristics of all 15 included trials and the 74 potentially eligible studies that 
were excluded due to insufficient outcome data. The majority of included trials published their main 
results after 2010, were parallel group, secondary prevention, multicentre and compared two 
randomised groups. A common primary outcome for the included trials was stroke, or a composite 
event that included stroke (14 trials, 93%); site investigators were more likely to have assessed the 
primary outcome blind to treatment allocation. Studies that were potentially eligible but not included 
due to insufficient essential information were similar, but tended to be from older publications, were 
more likely to be primary prevention trials, had recruited fewer participants, used fewer trial sites and 
were less likely to have occurrence of stroke as the primary outcome.      
Characteristics of central adjudication in included trials: 
For all included trials, central adjudicators were blinded to treatment allocation (Table 2). Blinding of 
central adjudicators to outcome assessment made by site investigators was either not done or not 
reported in 9 of the 15 trials. The number of adjudicators involved in each trial ranged from 2 to 28, 
and in over half the studies multiple adjudicators assessed each event. Disagreements between 
adjudicators were dealt with in a variety of ways, with use of an additional blinded adjudication the 
most common.  
Risk of bias: 
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Adjudicators commonly assessed only cases reported by site investigators, but for all ten trials where 
this occurred half the site investigators were not blind to treatment allocation. In total, five trials were 
assessed as low adjudication risk of bias. All studies were high quality according to the Cochrane risk 
of bias tool (see Supplemental material, Supplementary Table II). 
Impact of central adjudication on primary treatment effect size: 
The results of the primary analysis for all included trials using both outcome assessment by site 
investigators and central adjudicators are displayed in Figure 2. The meta-analysis of RTEs showed 
no evidence that adjudication altered estimates of treatment effect size when compared to 
assessment by site investigators (pooled RTE=1.02, 95% C.I: [0.95, 1.09], Figure 3). We found no 
evidence of any interaction between impact of adjudication on treatment effect estimates and blinding 
of site investigators to the trial allocation, number of participants randomised, number of trial sites, 
type of intervention or adjudication risk of bias (see Supplemental material, Supplementary Figures I-
V). The sensitivity analysis was consistent with the random-effects pooled meta-analysis result (see 
Supplemental material, Supplementary Figure VI).  
Impact of central adjudication on the number of events reported: 
We found evidence that central adjudication reduced the number of reported events (pooled 
OR=0.91, 95% C.I: [0.88, 0.95], Figure 4) when compared with the number of events reported by site 
investigators. 
Discussion: 
In this meta-analysis of 15 stroke trials, including nearly 70,000 patients, we found no evidence that 
central adjudication of the primary outcome had any substantive impact on the primary trial result. 
Exploration of a number of pre-specified subgroups, including trial size, intervention type and blinding 
status of site investigators supported this finding. However, we found evidence that adjudicating 
resulted in fewer events reported for the primary outcome. 
Our findings are consistent with two previous reviews. One included ten cardiovascular trials[7] and 
similarly found no effect of adjudication versus site reported events (ratio of odds ratios, ROR=1.00, 
95% C.I: [0.97, 1.02]). Another was a Cochrane Review[18] of subjective binary outcomes, across all 
clinical areas, that found adjudication in 47 trials to have no impact on treatment effect estimates 
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(ROR=1.00, 95% C.I: [0.97, 1.04]). The Cochrane Review did suggest, however, that adjudication 
might be important when site investigators are not blinded to treatment allocation. This could be due 
to knowledge of the allocation influencing decisions about the primary outcome[41, 42], but we found no 
evidence of this in our review. This could be because the outcomes in the trials included in our review 
(and thus commonly adjudicated in stroke trials) are predominantly objective. Therefore, if the primary 
focus of adjudication is to ensure validity of trial results, this process may be redundant for trials with 
objective outcomes.    
In addition, we found that site investigators over-reported the number of events for the primary 
outcome, which is consistent with a review of ten cardiovascular trials[7] that showed that adjudication 
reduced the number of reported events. However, this reduction of events had no effect on the 
primary analysis in both ours and the previous review, indicating that site investigators over-report 
events in a similar proportion in both treatment arms. Whilst this non-differential misclassification by 
site investigators will not affect the primary trial analysis, it could affect the comparison of the rate of 
the primary outcome relative to other events (e.g. bleeding with a new anticoagulant). This would 
influence the risk-benefit calculation of bleeding versus prevention of the primary event, which is 
important for both clinicians and regulators. However, it is important to note that the process of 
adjudication in many trials does not enable central adjudication to add events as adjudicators only 
assess events reported by site investigators. Thus, the extent that sites over-report events may not be 
as high as we found. Additionally, there may be other reasons to adjudicate in randomised trials, 
which can have benefits that are more difficult to quantify. Central adjudication could identify poorly 
performing sites or even act as a policing effect that strengthens local assessment as investigators 
assess outcomes that are to be adjudicated more thoroughly.  
Before the inclusion of central adjudication in a clinical trial, the costs should also be considered. In 
one cardiovascular trial[43], the total cost of the adjudication process was estimated at $125,000 or $72 
per adjudicated case. If regulators and academic reviewers continue to advocate adjudication for the 
purpose of ensuring validity of results, then trialists will have no choice but to include potentially 
redundant adjudication committees, which in turn will lead to excessive research waste[16, 17, 44]. In this 
review we have not attempted to estimate the cost of adjudication, but this appears to be the next 
challenge to establish the role of adjudication in clinical trials. If the cost can be accurately predicted, 
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then trialists can decide during the study design stage of a trial what they (and the funder and their 
reviewers) will be prepared to fund for adjudication and its potential, unmeasurable benefit.  
One limitation of our review is that whilst we identified a total of 89 trials that were potentially eligible, 
we only managed to receive data from 15 of these, even after three reminders[24]. A large proportion 
of studies that did not provide data mentioned that the unadjudicated data were not available, and it is 
possible that our review may have found different results had more trials provided data. However, the 
characteristics of the excluded studies were similar to those that were included, and the individual 
results from all 15 included trials agreed with the overall pooled estimate. Another limitation of our 
small sample size is that the included studies are high quality trials in respect to the usual 
components of risk of bias, and higher quality studies could have less need for adjudication than 
lower quality trials. Furthermore, our review largely included prevention stroke trials and studies with 
binary primary outcomes. A larger sample of trials that had greater variation in quality, type and 
outcome could potentially have different findings. In our protocol, we stated that we would investigate 
the impact of adjudication on RTE by subjectivity of the outcome, but we did not undertake this 
analysis. This was because all the included outcomes are common in stroke trials and are sufficiently 
objective to change clinical practice.  
Of further interest would be to identify the number of events that need to be misclassified before the 
RTE differs from one. This would give an estimate for the magnitude of disagreement required 
between central adjudicators and site investigators to alter the estimated treatment effect. In addition, 
for borderline cases (where one limit of the confidence interval for the estimated treatment effect lies 
close to the null value) even a small amount of misclassification could miss a genuine treatment 
effect. However, determining at the design stage whether a study risks failing to detect a treatment 
effect due to misclassification of outcomes by site investigators is challenging. We plan to conduct 
further research using simulation studies to investigate these questions. 
In summary, this review found no evidence that central adjudication of the primary outcome in stroke 
trials had any impact on estimated treatment effect size. However, central adjudication did control 
non-differential misclassification and limit over-reporting of events by site investigators. If the primary 
purpose of central adjudication is to ensure validity of trial conclusions, then these results suggest that 
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the potential advantages of central adjudication may not outweigh cost and time disadvantages in 
stroke studies. 
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Figures Legends: 
Figure 1: Flow diagram 
Figure 2: Analysis of 18 comparisons from 15 included trials, comparing the effect size for the primary 
outcome based on whether assessment was by central adjudicators or not 
Figure 3: Meta-analysis of RTE in included studies, using a random-effects model  
Figure 4: Meta-analysis of change in number of reported events in included studies, using a random-
effects model 
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Tables: 
Table 1: Characteristics of included trials and potentially eligible trials  
 Included (n=15) Potentially eligible, but 
data not received (n=74) 
p 
Year of main trial publication    
1990-2000 2 (13%) 5 (7%) 0.13* 
2001-2005 1 (7%) 9 (12%)  
2006-2010 2 (13%) 20 (27%)  
2011-2015 6 (40%) 35 (47%)  
2016-2018 4 (27%) 5 (7%)  
Study design    
Parallel 13 (87%) 70 (95%) 0.27* 
Factorial 2 (13%) 4 (5%)  
Type of trial    
Primary prevention 3 (20%) 34 (46%) 0.16* 
Secondary prevention 9 (60%) 30 (41%)  
Acute stroke 3 (20%) 10 (14%)  
Number of randomised groups    
2 12 (80%) 61 (82%) 0.86* 
3 1 (7%) 7 (9%)  
≥4 2 (13%) 6 (8%)  
Participants randomised    
Mean (SD) 4637 (5764) 3717 (5246) 0.33† 
Median [25th, 75th centile] 2885 [449, 6105] 1633 [439, 4576]  
Min, Max 129, 21105 48, 20702  
No. of sites    
Mean (SD) 216 (365) 185 (269) 0.59† 
Median [25th, 75th centile] 82 [50, 172] 85 [27, 179]  
Min, Max 4, 1393 1, 1178  
Not reported 0 (-) 5 (7%)  
Intervention    
Drug 9 (60%) 52 (70%) 0.39* 
Surgery/procedure 4 (27%) 18 (24%)  
Other 2 (13%) 4 (5%)  
Comparator    
Placebo 2 (13%) 14 (19%) 0.069* 
Standard care 10 (67%) 41 (55%)  
Active treatment 0 (-) 14 (19%)  
Surgery/procedure 2 (13%) 5 (7%)  
Other 1 (7%) 0 (-)  
Primary outcome    
Stroke 8 (53%) 20 (27%) 0.18* 
Composite including stroke 6 (40%) 39 (53%)  
Functional outcome after stroke 1 (7%) 6 (8%)  
Other 0 (-) 9 (12%)  
Blinding status of site 
investigators 
   
Blind to treatment allocation 9 (60%) 37 (50%) 0.48‡ 
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Data are n(%) unless otherwise stated 
*p-value from Fisher exact test 
†p-value from Mann-Whitney U test 
‡p-value from Chi-square test 
 
 
  
Not blind to  treatment allocation 6 (40%) 37 (50%)  
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Table 2: Characteristics of central adjudication in included trials 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are n(%) 
*Categories are not mutually exclusive 
 Total (n=15) 
Adjudicators blind to treatment allocation  
Yes 15 (100%) 
Adjudicators blind to assessment of the site 
investigators 
 
Yes 6 (40%) 
No 4 (27%) 
Not reported 5 (33%) 
Number of adjudicators   
2-4 9 (60%) 
5-9 2 (13%) 
≥10 4 (27%) 
Adjudicators profession*  
Neurologist 14 (93%) 
Cardiologist 3 (20%) 
Other health professional 5 (33%) 
Not a health professional 2 (13%) 
Not reported 1 (7%) 
Information provided to adjudicators*  
Medical notes 10 (67%) 
Original case report forms 11 (73%) 
Cranial scans 7 (47%) 
Audio recording 1 (7%) 
Video footage 1 (7%) 
Not reported 3 (20%) 
Number of adjudicators per case  
1 5 (33%) 
>1  9 (60%) 
Not reported 1 (7%) 
Method used to deal with disagreements  
Each event assessed by single adjudicator, so no 
disagreements 
4 (27%) 
Further adjudication 5 (33%) 
Consensus decision between 
adjudicators/committee 
4 (27%) 
Not reported 2 (13%) 
How cases were selected for adjudication  
Only those identified by unblinded site 
investigators  
5 (33%) 
Only those identified by blinded site investigators  5 (33%) 
All participants, or all suspected cases identified 
by blinded site investigators  
5 (33%) 
